220 related articles for article (PubMed ID: 33208919)
21. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
[TBL] [Abstract][Full Text] [Related]
22. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
23. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Complication Index Predicts Cancer-specific Survival After Resection of Colorectal Metastases Independent of RAS Mutational Status.
Yamashita S; Sheth RA; Niekamp AS; Aloia TA; Chun YS; Lee JE; Vauthey JN; Conrad C
Ann Surg; 2017 Dec; 266(6):1045-1054. PubMed ID: 27735824
[TBL] [Abstract][Full Text] [Related]
25. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
26. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
27. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and molecular characteristics of early-onset vs late-onset colorectal cancer according to tumor location.
Chen Y; Chen Z; Huang J; Hu J; He X; Lan P; He X
Int J Clin Oncol; 2022 Apr; 27(4):749-755. PubMed ID: 35079898
[TBL] [Abstract][Full Text] [Related]
29. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
[TBL] [Abstract][Full Text] [Related]
30. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center.
Gao XH; Li J; Liu LJ; Zheng NX; Zheng K; Mei Z; Bai CG; Zhang W
Int J Surg; 2022 Aug; 104():106780. PubMed ID: 35850466
[TBL] [Abstract][Full Text] [Related]
31. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.
Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN
Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476
[TBL] [Abstract][Full Text] [Related]
32. BRAF mutations and survival with surgery for colorectal liver metastases: A systematic review and meta-analysis.
Petrelli F; Arru M; Colombo S; Cavallone M; Cribiu' FM; Villardita V; Floris P; Digiesi L; Severgnini G; Moraes MT; Conti B; Celotti A; Viti M; Sozzi A
Eur J Surg Oncol; 2024 Jun; 50(6):108306. PubMed ID: 38603866
[TBL] [Abstract][Full Text] [Related]
33. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
34. Clinical, Pathological and Molecular Characteristics of Chilean Patients with Early-, Intermediate- and Late-Onset Colorectal Cancer.
Alvarez K; Cassana A; De La Fuente M; Canales T; Abedrapo M; López-Köstner F
Cells; 2021 Mar; 10(3):. PubMed ID: 33809084
[TBL] [Abstract][Full Text] [Related]
35. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
[TBL] [Abstract][Full Text] [Related]
36. Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer.
Arriba M; Sánchez C; Vivas A; Nutu OA; Rueda D; Tapial S; Rodríguez Y; Brandáriz L; García JL; García-Olmo D; Goel A; González-Sarmiento R; Urioste M; Perea J
PLoS One; 2019; 14(5):e0216472. PubMed ID: 31095598
[TBL] [Abstract][Full Text] [Related]
37. A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status.
Kawaguchi Y; Kopetz S; Lillemoe HA; Hwang H; Wang X; Tzeng CD; Chun YS; Aloia TA; Vauthey JN
J Natl Compr Canc Netw; 2020 Nov; 18(11):1500-1508. PubMed ID: 33152698
[TBL] [Abstract][Full Text] [Related]
38. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
[TBL] [Abstract][Full Text] [Related]
39. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.
Denbo JW; Yamashita S; Passot G; Egger M; Chun YS; Kopetz SE; Maru D; Brudvik KW; Wei SH; Conrad C; Vauthey JN; Aloia TA
J Gastrointest Surg; 2017 Jan; 21(1):68-77. PubMed ID: 27334313
[TBL] [Abstract][Full Text] [Related]
40. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
